Coronavirus: The mystery of ‘silent spreaders’

Scientists have discovered more evidence about a strange and worrying feature of the coronavirus

Share Button

NASA astronauts launch from America in historic test flight of SpaceX Crew Dragon

For the first time in history, NASA astronauts have launched from American soil in a commercially built and operated American crew spacecraft on its way to the International Space Station. The SpaceX Crew Dragon spacecraft carrying NASA astronauts Robert Behnken and Douglas Hurley lifted off at 3:22 p.m. EDT Saturday on the company’s Falcon 9 rocket from Launch Complex 39A at NASA’s Kennedy Space Center in Florida.

“Today a new era in human spaceflight begins as we once again launched American astronauts on American rockets from American soil on their way to the International Space Station, our national lab orbiting Earth,” said NASA Administrator Jim Bridenstine. “I thank and congratulate Bob Behnken, Doug Hurley, and the SpaceX and NASA teams for this significant achievement for the United States. The launch of this commercial space system designed for humans is a phenomenal demonstration of American excellence and is an important step on our path to expand human exploration to the Moon and Mars.”

Known as NASA’s SpaceX Demo-2, the mission is an end-to-end test flight to validate the SpaceX crew transportation system, including launch, in-orbit, docking and landing operations. This is SpaceX’s second spaceflight test of its Crew Dragon and its first test with astronauts aboard, which will pave the way for its certification for regular crew flights to the station as part of NASA’s Commercial Crew Program.

“This is a dream come true for me and everyone at SpaceX,” said Elon Musk, chief engineer at SpaceX. “It is the culmination of an incredible amount of work by the SpaceX team, by NASA and by a number of other partners in the process of making this happen. You can look at this as the results of a hundred thousand people roughly when you add up all the suppliers and everyone working incredibly hard to make this day happen.”

The program demonstrates NASA’s commitment to investing in commercial companies through public-private partnerships and builds on the success of American companies, including SpaceX, already delivering cargo to the space station.

“It’s difficult to put into words how proud I am of the people who got us here today,” said Kathy Lueders, NASA’s Commercial Crew Program manager. “When I think about all of the challenges overcome — from design and testing, to paper reviews, to working from home during a pandemic and balancing family demands with this critical mission — I am simply amazed at what the NASA and SpaceX teams have accomplished together. This is just the beginning; I will be watching with great anticipation as Bob and Doug get ready to dock to the space station tomorrow, and through every phase of this historic mission.”

SpaceX controlled the launch of the Falcon 9 rocket from Kennedy’s Launch Control Center Firing Room 4, the former space shuttle control room, which SpaceX has leased as its primary launch control center. As Crew Dragon ascended into space, SpaceX commanded the spacecraft from its mission control center in Hawthorne, California. NASA teams are monitoring space station operations throughout the flight from Mission Control Center at the agency’s Johnson Space Center in Houston.

The SpaceX Crew Dragon spacecraft is scheduled to dock to the space station at 10:29 a.m. Sunday, May 31. NASA Television and the agency’s website are providing ongoing live coverage of the Crew Dragon’s trip to the orbiting laboratory. Behnken and Hurley will work with SpaceX mission control to verify the spacecraft is performing as intended by testing the environmental control system, the displays and control system, and by maneuvering the thrusters, among other things. The first docking maneuver began Saturday, May 30, at 4:09 p.m., and the spacecraft will begin its close approach to the station at about 8:27 a.m. Sunday, May 31. Crew Dragon is designed to dock autonomously, but the crews onboard the spacecraft and the space station will diligently monitor the performance of the spacecraft as it approaches and docks to the forward port of the station’s Harmony module.

After successfully docking, the crew will be welcomed aboard the International Space Station, where they will become members of the Expedition 63 crew, which currently includes NASA astronaut Chris Cassidy. NASA will continue live coverage through hatch opening and the crew welcoming ceremony. The crew will perform tests on Crew Dragon in addition to conducting research and other tasks with the space station crew.

Three astronauts aboard the International Space Station will participate in a live NASA Television crew news conference from orbit on Monday, June 1, beginning at 11:15 a.m. on NASA TV and the agency’s website (www.nasa.gov/live).

Demo-2 Astronauts

Behnken is the joint operations commander for the mission, responsible for activities such as rendezvous, docking and undocking, as well as Demo-2 activities while the spacecraft is docked to the space station. He was selected as a NASA astronaut in 2000 and has completed two space shuttle flights. Behnken flew STS-123 in March 2008 and STS-130 in February 2010, performing three spacewalks during each mission. Born in St. Anne, Missouri, he has bachelor’s degrees in physics and mechanical engineering from Washington University in St. Louis and earned a master’s and doctorate in mechanical engineering from the California Institute of Technology in Pasadena. Before joining NASA, he was a flight test engineer with the U.S. Air Force.

Hurley is the spacecraft commander for Demo-2, responsible for activities such as launch, landing and recovery. He was selected as an astronaut in 2000 and has completed two spaceflights. Hurley served as pilot and lead robotics operator for both STS‐127 in July 2009 and STS‐135, the final space shuttle mission, in July 2011. The New York native was born in Endicott but considers Apalachin his hometown. He holds a Bachelor of Science degree in civil engineering from Tulane University in New Orleans and graduated from the U.S. Naval Test Pilot School in Patuxent River, Maryland. Before joining NASA, he was a fighter pilot and test pilot in the U.S. Marine Corps.

Mission Objectives

The Demo-2 mission is the final major test before NASA’s Commercial Crew Program certifies Crew Dragon for operational, long-duration missions to the space station. As SpaceX’s final flight test, it will validate all aspects of its crew transportation system, including the Crew Dragon spacecraft, spacesuits, Falcon 9 launch vehicle, launch pad 39A and operations capabilities.

While en route to the station, Behnken and Hurley will take control of Crew Dragon for two manual flight tests, demonstrating their ability to control the spacecraft should an issue with the spacecraft’s automated flight arise. On Saturday, May 30, while the spacecraft is coasting, the crew will test its roll, pitch and yaw. When Crew Dragon is about 1 kilometer (0.6 miles) below the station and moving around to the docking axis, the crew will conduct manual in-orbit demonstrations of the control system in the event it were needed. After pausing, rendezvous will resume and mission managers will make a final decision about whether to proceed to docking as Crew Dragon approaches 20 meters (66 feet).

For operational missions, Crew Dragon will be able to launch as many as four crew members at a time and carry more than 220 pounds of cargo, allowing for an increased number crew members aboard the space station and increasing the time dedicated to research in the unique microgravity environment, as well as returning more science back to Earth.

The Crew Dragon being used for this flight test can stay in orbit about 110 days, and the specific mission duration will be determined once on station based on the readiness of the next commercial crew launch. The operational Crew Dragon spacecraft will be capable of staying in orbit for at least 210 days as a NASA requirement.

At the conclusion of the mission, Behnken and Hurley will board Crew Dragon, which will then autonomously undock, depart the space station, and re-enter Earth’s atmosphere. Upon splashdown off Florida’s Atlantic coast, the crew will be picked up by the SpaceX recovery ship and returned to the dock at Cape Canaveral.

NASA’s Commercial Crew Program is working with SpaceX and Boeing to design, build, test and operate safe, reliable and cost-effective human transportation systems to low-Earth orbit. Both companies are focused on test missions, including abort system demonstrations and crew flight tests, ahead of regularly flying crew missions to the space station. Both companies’ crewed flights will be the first times in history NASA has sent astronauts to space on systems owned, built, tested and operated by private companies.

Learn more about NASA’s Commercial Crew program at: https://www.nasa.gov/commercialcrew

Share Button

New sunspots potentially herald increased solar activity

On May 29, 2020, a family of sunspots — dark spots that freckle the face of the Sun, representing areas of complex magnetic fields — sported the biggest solar flare since October 2017. Although the sunspots are not yet visible (they will soon rotate into view over the left limb of the Sun), NASA spacecraft spotted the flares high above them.

The flares were too weak to pass the threshold at which NOAA’s Space Weather Prediction Center (which is the U.S. government’s official source for space weather forecasts, watches, warnings and alerts) provides alerts. But after several months of very few sunspots and little solar activity, scientists and space weather forecasters are keeping their eye on this new cluster to see whether they grow or quickly disappear. The sunspots may well be harbingers of the Sun’s solar cycle ramping up and becoming more active.

Or, they may not. It will be a few more months before we know for sure.

As the Sun moves through its natural 11-year cycle, in which its activity rises and falls, sunspots rise and fall in number, too. NASA and NOAA track sunspots in order to determine, and predict, the progress of the solar cycle — and ultimately, solar activity. Currently, scientists are paying close attention to the sunspot number as it’s key to determining the dates of solar minimum, which is the official start of Solar Cycle 25. This new sunspot activity could be a sign that the Sun is possibly revving up to the new cycle and has passed through minimum.

However, it takes at least six months of solar observations and sunspot-counting after a minimum to know when it’s occurred. Because that minimum is defined by the lowest number of sunspots in a cycle, scientists need to see the numbers consistently rising before they can determine when exactly they were at the bottom. That means solar minimum is an instance only recognizable in hindsight: It could take six to 12 months after the fact to confirm when minimum has actually passed.

This is partly because our star is extremely variable. Just because the sunspot numbers go up or down in a given month doesn’t mean it won’t reverse course the next month, only to go back again the month after that. So, scientists need long-term data to build a picture of the Sun’s overall trends through the solar cycle. Commonly, that means the number we use to compare any given month is the average sunspot number from six months both backward and forward in time — meaning that right now, we can confidently characterize what October 2019 looks like compared to the months before it (there were definitely fewer sunspots!), but not yet what November looks like compared to that.

On May 29, at 3:24 a.m. EST, a relatively small M-class solar flare blazed from these sunspots. Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth’s atmosphere to physically affect humans on the ground, however — when intense enough — they can disturb the atmosphere in the layer where GPS and communications signals travel. The intensity of this flare was below the threshold that could affect geomagnetic space and below the threshold for NOAA to create an alert.

Nonetheless, it was the first M-class flare since October 2017 — and scientists will be watching to see if the Sun is indeed beginning to wake up.

Story Source:

Materials provided by NASA/Goddard Space Flight Center. Original written by Karen Fox and Lina Tran. Note: Content may be edited for style and length.

Share Button

Coronavirus: ‘Dangerous moment’ as UK lockdown eases

The public must be “sensible” after scientists warn of risks of lifting lockdown, medical chief says.

Share Button

The fight goes on: Clinical trial shows promising new treatment for rare blood cancer

Lymphoma is a type of blood cancer that develops from lymphocytes (a type of white blood cell). It has many subtypes. A rare subtype, called intravascular large B-cell lymphoma (or IVLBCL) is notably hard to diagnose accurately because the cancerous lymphocytes grow inside small blood vessels, instead of at lymph nodes, and there is no perceptible swelling/enlargement of lymph nodes. There is also no effective treatment: the disease tends to affect the elderly, for whom standard high-dose chemotherapy may have serious side-effects, and patients are at a high risk of developing subsequent central nervous system (CNS) disorders even with treatment. A novel treatment protocol with fewer side-effects and which also tackles secondary CNS involvement is needed, and this is exactly what a group of scientists, led by researchers from Nagoya University and Mie University, Japan, attempted to test in a new clinical trial.

All of this being said, however, the rarity of this disease has made testing new combinations of drugs difficult. A previous “retrospective” study involving the analysis of medical records of patients who had undergone standard chemotherapy combined with a drug called “rituximab” showed that this line of treatment is more promising than standard treatment alone, but it does not solve the problem of secondary CNS involvement. “We considered that rituximab-containing chemotherapies combined with treatment for the secondary CNS problems could lead to further improvement in the clinical outcome,” remarks Dr Kazuyuki Shimada of Nagoya University. With this consideration, Dr Shimada and team conducted a Phase 2 multicenter clinical trial, where they administered their proposed treatment to 38 enrolled patients (aged 20 to 79 years and without CNS disorders at the time of cancer diagnosis) and monitored their conditions over the long term. The results are published in their paper in The Lancet Oncology.

Overall, their treatment protocol appears to be promising: 76% of the enrolled patients reached the primary goal of two-year survival without disease progression and 92% reached two-year overall survival. The disease affected the CNS in only 3% of patients. What’s more, the toxicity of the treatment was found to be low, and all adverse effects were manageable, with very few serious complications.

Aptly summarizing their achievement, Dr Shimada says: “To the best of our knowledge, this is the first ‘prospective’ trial of any treatment in patients with IVLBCL. It appears that the proposed treatment protocol might be effective in patients without apparent central nervous system involvement at the time of diagnosis.”

An important advantage of the proposed treatment protocol is that it employs a combination of conventional drugs and uses no novel agents. This means that although further study is necessary, this protocol can be adopted in clinical practice in the very near future. As Dr Shimada explains: “Given the rarity of this disease, a large-scale Phase 3 prospective trial is not feasible. In such a scenario, the results of our trial provide a safe and effective treatment option that can function as a historic control for future prospective trials.”

The findings of this clinical trial are certainly quite promising. With only minor refinements to the proposed treatment protocol, patients with IVLBCL could have an edge in their fight against cancer.

Story Source:

Materials provided by Nagoya University. Note: Content may be edited for style and length.

Share Button

Coronavirus: Tory MPs call for change in 2m social distancing rule

Amid fears for the hospitality sector, one MP says relaxing the rule means fewer jobs would be lost.

Share Button

Business and Meaning

The world of business can provide an endless stream of activities, whether you have a job or run your own company. If you read books or take courses on advancing your career or growing your business, you’ll pick up even more to-do ideas.

I usually enjoy the world of business, but in order to keep my life in balance, I need to regularly refocus on the big picture and avoid drowning in busywork. Sometimes I have to step back from business to regain perspective.

Business can be addictive, whether it’s going well or not. When the results aren’t flowing, there’s a scramble to fix that. And when the results are flowing well, ambition can kick in and make you want to aim even higher. It’s easy to get caught up in these cycles and forget to ask: Why am I doing all this work? What’s the point?

What helps me stay in balance is reminding myself that all of this is temporary and that death is part of the roadmap – death for me and death for any business ventures I participate in. At some point it all ends, even if some of it outlives me.

This perspective helps me think about what’s worth doing and what isn’t. I think carefully about the meaning of the projects I put on my plate and whether they’re purposeful enough to justify the investment of time and energy. I want to feel that my business activities are enhancing my life and those of others. If the meaning isn’t there, however, it makes me feel that I’m spinning my wheels and speeding down the road towards death without enjoying the journey enough. And that realization motivates me to change course sooner or later.

Meaning isn’t static though. What may be a meaningful project one year may feel hollow in a different year. I have to keep checking in to see where the meaning can be found next. Sometimes I’ll find it on the creative side, other times on the social or contribution side, and sometimes in areas of fresh exploration or personal challenge.

I read a lot of business books, and I often find the meaning aspect lacking. Such books may share tips for greater efficiency and systematizing, but they often overlook why that matters. They talk about improving results, but not all business results will feel meaningful. Have you ever achieved results that others may applaud but that feel mostly meaningless to you? Do you want to do more hollow-feeling work?

Growing a business is often accepted as an assumed goal, but a business doesn’t have to grow bigger to deliver meaning and purpose. Sometimes growing bigger may run contrary to purpose, killing the joy in the operation and destroying the meaning. I’ve met people who’ve grown their businesses and seem less happy for it, and I’ve met people who’ve grown their businesses and seem to revel in the experience. One person’s meaning is another person’s albatross.

Even when an author shares the meaning and purpose that led them to make certain business improvements, their meaning may not motivate me in the same way. I still have to find my own meaning if I’m to apply the ideas with sustainable motivation. It’s hard to apply someone else’s ideas if I don’t root them to my own personal meaning.

One practice that works well for me is to incorporate meaning into my project designs. When I begin a major new project, such as creating a new course, I write up a design doc for it. This helps me think through the key details of the project in advance and look at the big picture. An important part of this doc is a section on personal meaning. I consider why I want to do the project and what it means to me, and I type up my answers. Even if I expect a project to create some external results, I still ask myself why I should care about those results.

Sometimes I don’t find enough meaning in a project, at least not in the initial version of it, but while it’s still in the design phase, I can tweak the design until I feel the meaning is strong enough. This can be surprisingly easy. A few small tweaks can make a world of difference. Simply deciding to do a project in a playful style can sometimes make it feel meaningful enough. Finding a meaning often comes down to approaching it from the right angle or framing it the right way, as opposed to doing a major redesign.

When a project feels deeply meaningful, that’s when I can commit to it. That’s when it feels like a worthwhile investment of my life energy. This kind of motivation sustains me.

See this as an invitation to find the beauty in each of your work projects. It’s probably there already if you look at each project from the right angle.

Why did you accept this assignment? Why do the work? Why does this matter to you? What will this do for your character growth? What makes this a worthy investment of your precious life?

Share Button

Health24.com | Prescriptions for discredited Covid drugs surged 2 000% after Trump’s support

  • There was a shortage of drugs to treat the conditions they are meant for
  • A few studies found that that the drugs could be dangerous in treating Covid-19
  • An expert says it’s reckless to encourage people to take them to treat the virus

A new study finds that prescriptions rose sharply for two drugs that President Donald Trump claimed could help prevent or treat Covid-19.

This happened despite the fact that multiple studies found the medicines might only bring harm to patients with coronavirus illness.

The study, conducted by researchers at Harvard-affiliated Brigham and Women’s Hospital in Boston, found that prescriptions for the two drugs – hydroxychloroquine and chloroquine – rose by a staggering 2 000% during the week of 15 March to 21 March.

Early in the pandemic, Trump repeatedly touted hydroxychloroquine and chloroquine as a potential means of preventing or treating coronavirus illness.

READ | More evidence hydroxychloroquine won’t help, may harm Covid-19 patients

No benefit to patients

On 21 March, Trump tweeted, “HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game-changers in the history of medicine.” Azithromycin is an antibiotic often used to fight infections.

But a slew of studies have all found that any early promise from the drugs has quickly fizzled.

Research conducted at multiple sites found that hydroxychloroquine provides no benefit to patients, and has even been tied to a higher rate of dangerous heart arrhythmias and death.

In fact, safety concerns over hydroxychloroquine prompted the World Health Organization to remove the drug from a global trial of potential Covid-19 therapies earlier this week.

Still, Trump said on Sunday he had just finished taking a two-week course of the malaria drug to guard against Covid-19 infection after two White House staffers tested positive for the coronavirus.

The new study sought to determine what influence statements made by Trump and others might have had on patient requests for hydroxychloroquine and chloroquine.

Dramatic surge in prescriptions

“There have been indications that hydroxychloroquine prescribing had increased and shortages had been reported, but this study puts a spotlight on the extent to which excess hydroxychloroquine/chloroquine prescriptions were filled nationally,” study co-author Dr Haidar Warraich said in a hospital news release.

His team tracked prescribing rates over a 10-week period: 16 February 16 to 25 April. Comparing rates to the same dates one year ago, the researchers tracked data on prescriptions for hydroxychloroquine/chloroquine, the antibiotic azithromycin, and the other top 10 most prescribed drugs in the United States.

They found that between 15 and 21 March prescriptions for azithromycin, amoxicillin and the painkillers hydrocodone/acetaminophen declined, and rates for heart medicines remained stable.

In contrast, there was a dramatic surge in prescriptions for hydroxychloroquine/chloroquine: from 2 208 prescriptions in 2019 to 45,858 prescriptions in 2020 – an increase of more than 2 000%.

And over the full 10 weeks of the study, there was an excess of almost a half-million prescription “fills” of hydroxychloroquine/chloroquine compared to the year before.

“This analysis doesn’t include patients who were prescribed hydroxychloroquine/chloroquine in a hospital setting,” Warraich noted. “This means that patients could have been taking the drugs at home, without supervision or monitoring for side effects.”

Suggestive of shortage

Hydroxychloroquine/chloroquine are legitimately used by people with lupus to help control the immune disorder. But the Brigham team say they noticed a concurrent decline in the types of long-term prescriptions those patients might require – suggestive of a shortage.

In fact, the US Food and Drug Administration began to report a drug shortage of hydroxychloroquine beginning on 3 March, the researchers noted.

All of this has physicians concerned.

Dr Matthew Heinz is a hospitalist and internist at Tucson Medical Center in Arizona. Reacting to Trump’s announcement earlier this month that he was taking the drug, Heinz said that, “I cannot stress enough how reckless it is to encourage anybody to take hydroxychloroquine or any other unproven remedy for SARS-CoV-2.”

“Chloroquine and hydroxychloroquine are not benign substances and can cause serious, sometimes life-threatening, adverse effects,” including sometimes fatal cardiac arrhythmias, he noted. “This is especially true when so many people already have underlying cardiac and other medical conditions – they are even more susceptible to such side effects.”

The new study was published on 28 May in the Journal of the American Medical Association.

Image credit: Getty Images

Share Button

Health24.com | 1 in 10 older patients with diabetes, hospitalised with Covid-19, dies – according to a new study

  • Study aimed to investigate how patients with diabetes were affected
  • Age also played a key role in outcomes – average age of people analysed was 70
  • Majority of the 1 300 people studied had type 2 diabetes

Ten percent of Covid-19 patients with diabetes die within a week of entering the hospital and 20% need a ventilator to breathe by that point, a new French study found.

Researchers analysed data on more than 1 300 Covid-19 patients with diabetes, average age 70, who were hospitalised in France during March. Of those, 89% had type 2 diabetes, 3% had type 1, and the rest had other types of diabetes.

The study found that one in five patients had been placed on a ventilator in intensive care within seven days of entering the hospital; one in 10 had died; and 18% had been discharged.

“The risk factors for severe Covid-19 [in patients with diabetes] are identical to those found in the general population: age and BMI [weight],” said researchers led by diabetes specialists Dr Bertrand Cariou and Dr Samy Hadjadj, from University Hospital Nantes.

Diabetic complications add to risk

The study was the first to investigate how Covid-19 affects patients with diabetes.

Poor blood sugar control didn’t appear to affect a patient’s outcome, but diabetic complications and older age were linked to increased odds of death.

So was a higher body mass index (BMI), an estimate of body fat based on weight and height. Patients with a higher BMI were also more likely to need a ventilator.

The study found that 47% of patients had complications of the eye, kidney or nerves (microvascular), and 41% had complications in the heart, brain and legs (macrovascular).

Those complications each more than doubled a patient’s risk of death at day seven of hospitalisation, according to the researchers.

Similar risk for men and women

Age was also key. Patients 75 years and older were 14 times more likely to die than patients under 55. Patients between 65 and 74 had triple the risk of death compared to those under 55.

In addition, obstructive sleep apnoea and shortness of breath almost tripled a patient’s risk of death, and higher BMI increased the odds of needing a ventilator or death, the study found.

Women were 25% less likely than men to die or need a ventilator, but the statistical difference was borderline, the researchers said. When they focused on death alone, the risk for men and women was about the same.

The findings were published on 28 May in the journal Diabetologia.

The study confirmed that insulin and other treatments for blood sugar control do not increase the odds of severe Covid-19 and should be continued in patients with diabetes, the authors said in a journal news release.

Image credit: Getty Images

Share Button

Health24.com | Scientists spot more genes linked to problem drinking

It was already known that genetics can play a role in drinking problems, but now researchers have identified additional gene variants that could help identify many more at-risk people.

The team conducted a genome-wide analysis of more than 435 000 people of European ancestry to look for shared gene variants among people with problem drinking.

The researchers pinpointed 19 new gene variants, along with 10 previously known ones, according to the study published on 25 May in the journal Nature Neuroscience.

“The new data triple the number of known genetic risk loci associated with problematic alcohol use,” said study senior author Joel Gelernter, a professor of psychiatry, genetics and neuroscience at Yale University School of Medicine.

Risk for problematic alcohol use

For the study, the researchers analysed genetic data from four biobanks, which also included information on genetic risk factors for several mental health disorders. This meant they could examine shared genetic associations between problem drinking and mental health disorders such as depression and anxiety.

In the study, the researchers also investigated how one genetically linked trait affects another genetically linked trait.

“This gives us ways to understand causal relations between problematic alcohol use traits such as psychiatric states, risk-taking behaviour, and cognitive performance,” said study lead author Hang Zhou, an associate research scientist in psychiatry at Yale.

“With these results, we are also in a better position to evaluate individual-level risk for problematic alcohol use,” Gelernter explained in a Yale news release.

Image credit: 

Share Button